Characteristics of triple-negative breast cancer by de Ruijter, Tim C. et al.
REVIEW
Characteristics of triple-negative breast cancer
Tim C. de Ruijter • Ju ¨rgen Veeck •
Joep P. J. de Hoon • Manon van Engeland •
Vivianne C. Tjan-Heijnen
Received: 27 September 2010/Accepted: 20 October 2010/Published online: 11 November 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Background Triple-negative breast cancers (TNBC) nei-
ther express hormone receptors, nor overexpress HER2.
They are associated with poor prognosis, as deﬁned by low
ﬁve-year survival and high recurrence rates after adjuvant
therapy. Overall, TNBC share striking similarities with
basal-like breast cancers (BBC), so a number of studies
considered them being the same. The purpose of this
review is to summarise the latest ﬁndings on TNBC con-
cerning its relation and delineation to BBC, discuss the
developmental pathways involved and address clinical
implications for this complex type of breast cancer.
Methods The recent literature from PubMed and Medline
databases was reviewed.
Results Not all TNBC are of the intrinsic BBC subtype
(nonbasal (NB)-TNBC), nor are all BBC triple-negative
(non-triple-negative (NTN)-BBC). There is increasing
evidence that a triple-negative, basal-like breast cancer
(TNBBC) subtype develops mainly through a BRCA1-
related pathway. Somatic mutations that contribute to
NTN-BBC and NB-TNBC development are possibly not
related to this pathway, but may occur randomly due to
increased genomic instability in these tumours. Several
therapeutic options exist for TNBBC, which exhibited
promising results in recent clinical trials. Cytotoxic thera-
pies, e.g. combined treatment with anthracyclines or
taxanes, achieved good tumour regression rates in the neo-
adjuvant setting, but also showed considerable recurrence
during the ﬁrst 5 years after therapy. Targeted therapy
options involve PARP1 and EGFR inhibition, although
both approaches still need further investigation.
Conclusions TNBC and BBC are not the same disease
entity. The TNBBC subtype shows the largest homogeneity
in terms of tumour development, prognosis and clinical
intervention options.
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Introduction
Worldwide, 1.3 million women were estimated to be
diagnosed with breast cancer in 2007 (Garcia et al. 2007)
Therapeutic options for this type of cancer range from
primary surgery to adjuvant chemotherapy, radiotherapy,
hormonal therapy or targeted therapy. Breast cancer is a
heterogeneous disease, and therefore, no golden standard
therapy exists suitable for all tumours of the mammary
gland (Early Breast Cancer Trialists’ Collaborative Group
2005). For many years, tumours of the breast were char-
acterised by tumour size only. However, this sub-classiﬁ-
cation proved to be limiting for it was unable to deﬁne
subgroups sharing similar prognostic and therapeutic
aspects. Later on, a histological classiﬁcation system was
developed, dividing breast cancer into subgroups distin-
guished by the histological appearance of the tumour.
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alone, a histo-morphological subdivision also failed to
form homogeneous breast cancer subgroups (Weigelt et al.
2008; Page 2003). Currently, the most widely used clas-
siﬁcation system of breast cancer combines histo-mor-
phological information (such as histological subtype and
grading) as well as TNM staging information, i.e. tumour
size (T) together with lymph node (N) and distant metas-
tasis occurrence (M) (Elston and Ellis 1993; Sobin et al.
2009). A more recent approach to classify breast cancer
subgroups is that of gene expression proﬁling. Based on
transcriptomic similarity, breast carcinomas can be distin-
guished as part of a group of ﬁve distinct breast cancer
subtypes, of which the basal-like subtype is characterised
by aggressive tumour growth and poorest patient survival
(Sorlie et al. 2001, 2003).
Certain breast cancer treatment strategies, like hormonal
therapy (e.g. anti-oestrogens) or targeted therapy (e.g.
trastuzumab), are only effective when corresponding
receptors and targets are expressed by the tumour cell. In
breast cancer, a hormonal therapy requires oestrogen (ER)
and/or progesterone receptor (PgR) expression to be
effective, while trastuzumab therapy applies only to those
tumours harbouring overexpression of HER2 due to
ampliﬁcation of its encoding oncogene ERBB2. Hormonal
therapy and trastuzumab cause less adverse side effects
when compared to chemotherapy and prolong disease-free
survival (DFS) and overall survival (OS) of the patient
(Samphao et al. 2009; Pienkowski and Zielinski 2010).
However, some tumours neither express ER and PgR, nor
do they overexpress HER2, for why these tumours were
termed triple-negative breast cancer (TNBC). The prog-
nosis of patients with this type of tumour is very poor,
not only because hormonal therapy and treatment with
trastuzumab are ruled out, but also because these tumours
seem to be more aggressive than other breast carcinoma
subtypes (Nofech-Mozes et al. 2009), similar to those of
the basal-like breast cancer subtype.
The objective of this review is to summarise the latest
ﬁndings on TNBC. It will address the following questions:
What is the relation between the basal-like subtype and
TNBC? What pathways are involved in the growth of these
tumours? Do TNBC have a homogeneous gene expression
proﬁle? What is the prognosis of this kind of tumour? and
What are the most effective forms of treatment?
Triple negativity and the basal-like subtype of breast
cancer
Classically, breast carcinomas can be divided into 18 dif-
ferent subtypes based on histo-morphological characteris-
tics (Tavassoli and Devilee 2003). A large majority of
breast tumours (50–80%) is designated as ‘invasive ductal
carcinoma not otherwise speciﬁed’ (IDC NOS) (Weigelt
et al. 2008). IDC NOS is deﬁned as a tumour that fails to
exhibit sufﬁcient morphological features to be categorised
as one of the other 17 subtypes (Page 2003; Tavassoli and
Devilee 2003; Weigelt et al. 2008). Unfortunately, the
histological way of categorising breast tumours fails to
divide tumours into different entities of the disease with
type-speciﬁc prognosis and treatment possibilities. In par-
ticular, the largest IDC NOS subtype shows an inhomo-
geneous prognosis (Weigelt et al. 2008). Moreover, the
accuracy of histological classiﬁcation depends greatly on
the pathologist (Page 2003; Weigelt et al. 2008). A new
approach to characterise breast tumours using molecular
characteristics was ﬁrst described by Sorlie et al. (2001).
This study group clustered breast carcinomas based on
similar gene expression proﬁles, as determined by DNA
microarray experiments. The largest overall difference in
gene expression was observed between hormone receptor
(HR)-positive and HR-negative tumours. HR-positive
tumours clustered in two groups with expression patterns
similar to luminal epithelial mammary cells. HR-negative
tumours clustered in three distinct molecular subgroups:
tumours with gene expression similar to basal/myoepithe-
lial mammary cells; tumours with characteristics of HER2
gene ampliﬁcation; and tumours with expression patterns
related to normal mammary stromal cells. The subtypes
thus found are referred to as luminal A, luminal B, basal-
like, HER2-positive and normal-like breast cancer (Sorlie
et al. 2001), all of which are associated with distinct
prognosis and treatment possibilities. Interestingly, the
normal-like breast carcinomas do not seem to constitute a
true subtype. It is assumed that it represents breast cancer
samples in which normal breast cells are overrepresented,
suggesting that gene expression results reﬂect a non-cancer
cell expression rather than that of the cancerous cells
(Sorlie et al. 2001; Morris and Carey 2007).
Basal-like breast cancer (BBC) is associated with triple
negativity of an ER/PgR/HER2 status (Sorlie et al. 2001).
Therefore, several studies have used the absence of these
receptors, sometimes along with cytokeratin 5/6 or cyto-
keratin 17 expression, as a characteristic feature to deﬁne
BBC in histological staining (Nielsen et al. 2004). How-
ever, a study by Bertucci et al. (2008) showed that TNBC
and BBC are not the same entity. Using gene expression
proﬁling, only 123 samples of the 172 triple-negative
tumours (71%) were determined to cluster with BBC,
suggesting that not all TNBC are of the basal-like subtype.
Reversely, only 123 (77%) of the 160 tumours that were
deﬁned as BBC by gene expression proﬁling proved to be
triple-negative in histological staining, indicating that not
all BBC are triple-negative. In further studies, Morris et al.
(2007) and Rakha et al. (2009) showed similar results. In
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123addition, these studies showed that TNBC do not form a
homogeneous group when analysed by gene expression
proﬁling. In contrast, the basal-like subtype does form a
homogeneous group of tumours with a similar gene
expression proﬁle related to prognosis and therapy
response (Bertucci et al. 2008; Rakha et al. 2009). This
indicates that the prognosis of TNBC may actually refer to
the high percentage of triple-negative tumours that is of the
basal-like subtype (Cheang et al. 2008). Indeed, several
studies reported a poor disease-speciﬁc survival for the
basal-like subtype (Sorlie et al. 2003; Nielsen et al. 2004;
Carey et al. 2006; Morris et al. 2007). Furthermore, in
cases in which metastasis occurred, the disease-free sur-
vival interval was found to be signiﬁcantly shorter (Sorlie
et al. 2003). Also, at primary diagnosis, basal-like tumours
show adverse characteristics, such as a high nuclear and
mitotic grade and unfavourable histological features, like
high mitotic index and poor differentiation (Carey et al.
2006).
In conclusion, the triple-negative group of breast cancer
is not a homogeneous disease entity. However, a sub-
stantial fraction of these tumours belongs to the basal-like
tumour type, which does form a homogeneous group. Thus,
the overall poor prognosis of TNBC may be a result of this
basal-like subgroup, and triple negativity may be seen more
as a symptom than as a separate entity of breast cancer.
TNBC expression proﬁles and pathways leading
to the triple-negative or basal-like subtype
Although TNBC and BBC are not the same entity of the
disease, there is a large overlap between them. As a con-
sequence, many studies concerning gene expression and
cellular pathways in the development of different subtypes
of breast cancer do not distinguish between TNBC and
BBC. Moreover, evidence is present for a pathway that is
related to the BRCA1 pathway that leads to the develop-
ment of a basal-like, triple-negative subtype (TNBBC).
This evidence will be discussed later on in this section. We
propose a model in which non-basal-like TNBC (NB-
TNBC) and non-triple-negative BBC (NTN-BBC) are
possibly not the direct result of this pathway, but receive
their distinctive genotype because of random mutations.
For example, if a breast tumour develops following dis-
ruption of the BRCA1-related pathway, it might turn into
TNBBC. However, because of the instable genome, it is
possible that genomic changes occur that are not BRCA1
pathway related (Fig. 1). If these genomic changes involve,
for example, HER2 gene ampliﬁcation, the tumour will no
longer be TNBBC, but NTN-BBC. Since the tumour ben-
eﬁts from HER2 overexpression, there exists a selective
pressure towards HER2 ampliﬁcation. This could be the
explanation for the approximately 20–30% of BBC that are
not triple-negative. Likewise, in non-basal-like tumours, a
selective pressure is present towards losing HR expression,
since this enables the tumour to grow independently from
the presence or absence of growth-stimulating factors. This
may represent the cause of the approximately 20–30% of
TNBC that are not of the basal-like subtype.
The three subgroups of TNBC and BBC show a dif-
ferent prognosis and imply distinct therapeutic options.
Especially, NB-TNBC do not behave like TNBBC, for they
show better prognosis despite less response to adjuvant
chemotherapy (Rouzier et al. 2005; Rody et al. 2007;
Tischkowitz et al. 2007). This is why in the remainder of
this section of the review we will discuss the TNBBC
subtype as deﬁned by Sorlie et al. (2001).
TNBBCs have a speciﬁc expression proﬁle that distin-
guishes them from other breast tumours, e.g. enhanced
expression of Ki-67, vimentin, laminin and p53, whereas
expression of Bcl-2 is lower than in other subtypes
(Rodriguez-Pinilla et al. 2007; Han et al. 2008). Several
studies found expression of the tumour suppressor PTEN
more frequently lost in TNBBC than in non-TNBC (Perren
et al. 1999; Saal et al. 2008; Hu et al. 2009). PTEN plays a
role in the phosphatidylinositol 3-kinase pathway, which is
crucially involved in many breast cancer subtypes. Inter-
estingly, if this pathway is affected in breast cancer, either
PTEN or PIK3CA expression is lost, indicating that loss of
one gene’s activity may relieve the selective pressure on
losing the other (Saal et al. 2005). Loss of PTEN expres-
sion is associated with a triple-negative phenotype,
whereas downregulation of PIK3CA is associated with a
triple-positive phenotype (Perren et al. 1999; Saal et al.
2005, 2008). Other genes that tend to be mutated more
frequently in TNBBC compared to other breast tumours are
the tumour suppressor retinoblastoma gene (RB1) and the
KRAS oncogene, both well known to enhance tumour
growth (Hu et al. 2009).
Besides mutations, other genetic changes such as copy
number alterations (CNA) occur differentially between
distinct subtypes. Hu et al. (2009) observed that globally,
CNA occur more often in TNBBC than in any other sub-
type. However, neither the functional impact of these
lesions nor the frequency at which one speciﬁc CNA
occurred could match those of the HER2 ? subtype. In
more than 30% of the TNBBC cases, two speciﬁc CNA are
found, i.e. gene ampliﬁcation and chromosomal deletion
(Han et al. 2008; Hu et al. 2009). A gene that was found to
be speciﬁcally ampliﬁed in TNBBC is nuclear factor 1/B
(NFIB), residing on the short arm of chromosome 9. The
function of this gene in cancer biology has to be deﬁned
yet; however, it plays a known role in central nervous
system development (Han et al. 2008; Mason et al. 2009).
A structural deletion of 80 Mb on chromosome 5q13-14
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123that occurs more frequently in TNBC contains the RASA1
gene. This gene has a function in de-activating RAS, and
loss of RASA1 results in an overactive RAS tyrosine
kinase. Since RAS is a stimulator of cell growth, RAS
overactivation leads to increased proliferation activity (Hu
et al. 2009). NFIB and RASA1 are not the only genes
playing a key role in tumorigenesis by CNA. A study
comparing gene expression signatures reﬂecting chromo-
somal instability with signatures of the different breast
cancer subtypes revealed that TNBBC, along with the
HER2 ? subgroup, displays the most instable genome.
They also found that mutations in the PTEN and RB1 gene
are associated with this chromosomal instability (Hu et al.
2009).
In search of pathways that lead to the development of
TNBBC, several studies have found that BRCA1-related
breast cancers are associated with the TNBBC subtype
(Foulkes et al. 2003; Lakhani et al. 2005; Diaz et al. 2007),
and TNBBC expression proﬁles resemble those of BRCA1-
related breast cancers (Foulkes et al. 2003). This resem-
blance gave rise to the idea that BRCA1 mutations could
play a role in the development of TNBBC. Further ﬁndings
support this idea. For example, the earlier mentioned
deletion in chromosome 5q found in TNBBC is also asso-
ciated with BRCA1-related breast cancer, occurring in 71%
of cases (Johannsdottir et al. 2006; Hu et al. 2009). More-
over, abnormalities in the inactive X chromosome (Xi) that
destabilise its silenced state and activate genes that are
inactive in non-cancerous cells are associated with loss of
BRCA1 function (Ganesan et al. 2002), and they are also
associated with TNBBC (Richardson et al. 2006; Turner
et al. 2007). Taken together, these ﬁndings support the
hypothesis that loss of BRCA1 function may play a major
role in TNBBC development (Richardson et al. 2006).
Since not all TNBBC harbour mutations in BRCA1,i t
appears that it is not structural mutations alone to be nec-
essary for the development of TNBBC. Several studies
have investigated epigenetic changes, such as DNA
methylation, inﬂuencing the expression of BRCA1 in
TNBBC. However, DNA methylation does not seem to
play a supportive role, since BRCA1 methylation occurs
similar frequent in TNBBC and non-TNBBC (Turner et al.
2007; Matros et al. 2005). In contrast, Turner et al. (2007)
compared BRCA1 expression in TNBBC to BRCA1
expression in other tumour types and found that expression
in TNBBC was twofold lower. In addition, the expression
levels of inhibitor of DNA binding 4 (ID4), representing a
negative regulator of BRCA1 (Beger et al. 2001), proved to
be ninefold higher in TNBBC (Turner et al. 2007). This
implies that low BRCA1 expression could also be the result
of gene regulatory mechanisms, such as ID4 overexpres-
sion in these tumours. Still, the fact that not all TNBBC
show loss of BRCA1 expression suggests that further genes
related to the BRCA1 pathway are likely to be deregulated
in the process of TNBBC development (Richardson et al.
2006).
Several studies linked TNBBC to epidermal growth
factor receptor (EGFR) expression, and percentages
BBC N-BBC
NTN-BBC TNBBC NB-TNBC
TNBBC
NB-TNBC NTN-BBC
Loss of HR expression by 
BRCA1-related pathway; 
HER2 amplification by random 
mutation
Loss of HR expression by 
BRCA1-related pathway
Loss of HR expression by 
random mutation
Fig. 1 Origin and related
pathways of different types of
triple-negative and basal-like
breast tumours. The non-basal-
like triple-negative breast
cancers (NB-TNBC) may
originate from non-basal-like
breast cancer (N-BBC), and the
non-triple-negative basal-like
breast cancer (NTN-BBC) as
well as triple-negative basal-like
breast cancers (TNBBC) may
originate from basal-like breast
cancers (BBC). Only the
TNBBC subtype can be
regarded as a homogeneous
breast cancer subgroup
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123ranging from 42 to 71% were found (Nielsen et al. 2004;
Nalwoga et al. 2008; Cheang et al. 2008; Meche et al.
2009; Collins et al. 2009). This receptor, like HER2, is a
potent stimulating factor of cell-growth-activating path-
ways and thus stimulates tumour growth when activated
(Burgess 2008). EGFR expression in breast cancer is
associated with poor disease outcome. Viale et al. (2009)
showed worse disease-free survival (DFS), overall survival
(OS) and distant disease-free survival (DDFS) for EGFR
expressing TNBBC compared to tumours without EGFR
expression. Also, response rates of EGFR-positive breast
tumours to chemotherapeutic therapy proved to be lower
(Nogi et al. 2009). EGFR expression could be one of the
causes of the poor disease outcome of TNBBC. Since
EGFR can be targeted by newly developed therapies,
assessment of EGFR expression, like commonly performed
on HER2, could have major therapeutic relevance, as will
be described later in this review (Stratford et al. 2007;
Hoadley et al. 2007).
Prognostic implications of triple-negative breast cancer
Since most prognostic research is performed as retrospec-
tive studies, many of these studies use data collected for
diagnostic reasons. Mostly, these studies do not investigate
markers for basal-like breast cancer and use triple nega-
tivity as an inclusion factor to select their study population.
This is why in the following section prognosis is being
discussed for TNBC, rather than speciﬁcally for TNBBC.
Patients with TNBC suffer from poor prognosis (Nof-
ech-Mozes et al. 2009). Compared to other breast cancer
subtypes, TNBC develop earlier in life, and consequently
more often in pre-menopausal women (Carey et al. 2006;
Rhee et al. 2008). At diagnosis, TNBCs are commonly of
high nuclear mitotic grade, of larger tumour size, and they
show a more aggressive expression proﬁle with low Bcl-2
but high p53 and Ki67 expression (Foulkes et al. 2004;
Fulford et al. 2006; Tian et al. 2008; Dogan et al. 2008;
Nishimura and Arima 2008; Chivukula et al. 2008). Taken
together, these adverse factors may be a major reason for
poorer OS, breast-cancer-speciﬁc survival (BCSS) and
relapse-free survival (RFS) reported for this disease. Sev-
eral studies demonstrated signiﬁcantly lower RFS in
patients with TNBC compared to patients with non-TNBC.
Rhee et al. found that the four-year survival of TNBC
patients was 85.5%, compared to 94.2% in non-TNBC
patients (Rhee et al. 2008). Parikh et al. (2008) showed that
the frequency of relapse is less favourable in TNBC. Also,
the median time to tumour recurrence proved to be
1.2 years shorter in patients with TNBC when compared to
non-TNBC patients. Likewise in recurrent breast cancer,
those patients with TNBC still had a worse prognosis than
non-TNBC. Not only the risk of tumour recurrence was
higher, but also the risk of dying as a consequence of this
relapse. Mersin et al. (2008) reported a hazard ratio of 4.2
for developing tumour recurrence for TNBC when com-
pared to non-TNBC. Similar results for RFS in TNBC are
widely reported (Sorlie et al. 2003; Rakha et al. 2007; Dent
et al. 2007; Tian et al. 2008; Nishimura and Arima 2008;
Kaplan and Malmgren 2008). Overall ﬁve-year survival
was determined to be 81% for TNBC compared to 91% for
triple-positive breast cancer, and 94% for HR-positive/
HER2-negative (HR?/HER2-) breast cancer (Kaplan and
Malmgren 2008). Like RFS, shorter OS in TNBC is widely
reported (Dent et al. 2007; Tian et al. 2008; Nishimura and
Arima 2008; Chivukula et al. 2008). There is only one
breast cancer subtype that has a prognosis comparably poor
as TNBC. This is the HR-negative, HER2-positive (HR-/
HER2?) subtype. BCSS of this subgroup is reported as
86%, compared to 88% in the TNBC subgroup and 95% in
the triple-positive group (Kaplan and Malmgren 2008).
However, it should be noted that the recently published
long-term studies on breast cancer survival mostly included
patients during the pre-trastuzumab era. The introduction
of trastuzumab as therapy regimen signiﬁcantly improved
the prognosis in the HR-/HER2? subgroup (Pienkowski
and Zielinski 2010). Interestingly, it seems that the higher
risks of recurrence and tumour-related death diminish over
time. After 5 years of therapy, each type of risk is lowered
and almost equals those of the non-TNBC subtypes (Dent
et al 2007; Hergueta-Redondo et al. 2008). This suggests
that the poor prognosis of TNBC may be due to effects that
occur during the ﬁrst 5 years after surgery.
Therapeutic options of triple-negative breast cancer
In general, adjuvant therapeutic options for TNBBC can be
divided into two groups, cytotoxic agents and targeted
therapies. Cytotoxic agents confer a DNA-damaging effect
to generally all dividing cells. Fast dividing cells, like
cancer cells, are more susceptible to cytotoxic therapy, but
so are other fast dividing normal cells, like blood cells.
This is why cytotoxic agents often result in numerous
adverse side effects. In contrast, targeted therapies interfere
with a speciﬁc biomolecule to which their effect is direc-
ted. This target is a speciﬁc characteristic of the cancerous
cell, e.g. an overexpressed receptor, providing certain
selectivity against malignant cells, thereby being ineffec-
tive or less effective on normal cells (Tan and Swain 2008).
The short-term effects of cytotoxic agents are greater in
TNBBC than in any other breast cancer subtype (Carey
et al. 2007). Patients with TNBBC have increased patho-
logic complete response (pCR) rates compared to non-
TNBC patients, especially to taxanes and anthracycline
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(2009) found a pCR of 38% in TNBBCs, compared to 14%
in non-TNBBCs when treated with taxane in combination
with anthracycline agents. Similar results were found by
Liedtke et al. (2008). In spite of the better response to
chemotherapy, the prognosis of TNBBC is still worse than
that of other breast cancer subtypes, due to a higher like-
lihood of relapse in patients with residual disease (Rouzier
et al. 2005; Dent et al. 2007; Carey et al. 2007).
Another group of cytotoxic agents showing good results
in TNBBC are the platinum-containing agents, such as
cisplatin and carboplatin (Tan and Swain 2008). To date,
only few studies on the effect of these platinum-containing
agents in TNBBC have been completed. One study by
Sirohi et al. (2008) reported a clinical response rate of 88%
in TNBBC after neo-adjuvant treatment with platinum-
containing cytotoxic agents, compared to 55% clinical
complete response rate in other breast tumours. However,
the overall ﬁve-year survival was still worse for TNBBC
compared to tumours of other subtypes.
Targeted therapies are currently being developed or
evaluated for TNBBC, including inhibition of Poly [ADP-
ribose] polymerase 1 (PARP1) and EGFR, the latter also
known as HER1. However, none of these therapies have
yet reached approval level by the US. Food and Drug
Administration (FDA) (Tan and Swain 2008). PARP1 is an
enzyme that has an important function in the repair of DNA
single-strand breaks (SSB) as a part of the base excision
repair pathway (Dantzer et al. 2000). In this pathway,
PARP1 binds to the exposed ends of the corrupted DNA
strand and recruits essential enzymes needed to repair
SSBs. When PARP1 is inhibited, the base excision repair
pathway fails, which leads to accumulation of SSBs. In a
replicating cell entering the S-phase, replication is arrested
at a SSB site, leading to a DNA double-strand break
(DSB).
Inhibition of PARP1 leads to more single-strand breaks
in all cells, so why is it a targeted therapy? In healthy cells,
DSBs lead to the activation of a repair mechanism referred
to as homologous recombination. Since homologous
recombination uses an intact DNA strand as a template,
this mechanism is accurate and error-free. An important
mediator in this pathway is BRCA1. In the absence of
BRCA1, DSBs cannot be repaired by homologous recom-
bination, and cells activate an alternative repair pathway
termed non-homologous end joining (NHEJ). Intriguingly,
NHEJ is highly error-prone. Thus, in BRCA1-deﬁcient
cells, the damage executed by PARP inhibitors leads to
accumulation of structural DNA lesions, which results in
genomic instability and ﬁnally apoptotic cell death. Since
BRCA2 operates in the same pathway like BRCA1, deﬁ-
ciency of this protein renders the cell vulnerable to PARP
inhibitors as well (D’Amours et al. 1999; Tutt and
Ashworth 2002). Preclinical in vivo models investigating
the effectiveness of PARP inhibitors in the triple-negative/
basal-like setting have shown signiﬁcant tumour regres-
sion, longer DFS and OS in mice (Rottenberg et al. 2008).
When applying a dose non-cytotoxic for healthy cells in
mouse models carrying a BRCA2 mutation, similar effects
were achieved (Kyle et al. 2008; Hay et al. 2009).
Recently, several phase I and phase II trials of PARP
inhibitors have been performed with BRCA1 mutation
carriers, showing promising anti-tumour activity and only
few adverse side effects. For instance, in a phase I trial, the
PARP inhibitor olaparib (AZD2281) showed selective
activity against BRCA1/2-mutated breast cancer, whereas
BRCA-unrelated tumours remained unaffected (Fong et al.
2009). Based on this ﬁnding, Tutt et al. (2010) demon-
strated in a phase II trial on efﬁcacy, safety and tolerability
employing solely BRCA1/2 mutation carriers that olaparib
at a higher dose was also associated with an improved
objective response rate, while toxicity in BRCA1/2 muta-
tion carriers was similar low to that reported for patients
without BRCA mutations. In a further randomised phase II
trial, another PARP inhibitor, BSI-201, showed signiﬁ-
cantly increased OS in combination with gemcitabine and
carboplatin when compared to the standard regimen alone,
in heavily pre-treated patients. Importantly, this trial
recruited TNBC only and showed in parallel that TNBC
also exhibited signiﬁcantly elevated PARP1 expression
levels in contrast to normal breast tissue (O’Shaughnessy
et al. 2008). An important question here is that of how to
select the right patient population among TNBC subtypes
most likely to respond to inhibition of PARP. Addressing
this question, several scenarios have recently evolved. As
previously mentioned, BRCA1/2 genotyping may be ben-
eﬁcial, as these tumours affected by mutation show large
overlap with the TNBC phenotype. In another study,
TNBC were shown to express PARP1 more frequently than
other breast cancer subtypes (von Minckwitz et al. 2010).
High levels of PARP1 expression also correlated with
improved response to chemotherapy, so it is intriguing to
see whether levels of PARP1 expression may also predict
response to olaparib or BSI-201 in combination with con-
ventional chemotherapy, a trial that is currently being ini-
tiated by the respective study group (von Minckwitz et al.
2010). Third, other disruptions of DNA damage repair may
also contribute to PARP inhibitor sensitivity. For instance,
gene inactivation by promoter methylation of BRCA1 is a
common lesion among sporadic breast tumours (Esteller
et al. 2000). Interestingly, BRCA1-methylated and BRCA1-
mutated breast cancers exhibit similar transcriptional pro-
ﬁles (Hedenfalk et al. 2001). A recent study revealed that
the frequency of BRCA1 methylation is elevated among
TNBC, and the inhibition of PARP in BRCA1-methylated
breast cancer cell lines is similar effective as in BRCA1-
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ing that also BRCA1-methylated sporadic breast cancers
might be susceptible to PARP inhibitors. In summary,
further parameters may become valuable biomarkers of
PARP inhibitor response among patients with TNBC.
These parameters should be assessed in current and
ongoing future trials as stratifying biomarkers of response
among TNBC in order to identify the population with the
greatest beneﬁt of this kind of treatment. Despite these
promising ﬁndings, Edwards et al. discovered resistance to
PARP inhibitors developing in tumour cells as a result of a
deletion in BRCA2, reactivating the disabled gene
(Edwards et al 2008). Besides from using PARP inhibitors
as (neo)adjuvant therapy, it has been suggested as a pre-
ventive strategy. In patients with an inherited BRCA1/2
mutation, preventive use of PARP inhibitors may eliminate
any cell developing a second BRCA1/2 hit, before it
advances further to cancer (Helleday et al. 2005). More
research on the long-term effects of PARP inhibitor use
needs to be performed before preventive use of PARP
inhibitors can be considered.
As described earlier, TNBBC is more likely to express
EGFR than other breast cancer subtypes (Nielsen et al.
2004; Cheang et al. 2008; Meche et al. 2009; Collins et al.
2009; Nalwoga et al. 2008). The EGF receptor stimulates
cell replication similar to HER2. If targeted, the stimulating
effect of EGFR could be diminished, resulting in tumour
growth arrest or even tumour regression. EGFR can be
targeted by two types of agents, monoclonal antibodies
(mAbs) and small molecule tyrosine kinase inhibitors
(TKIs). MAbs target the extracellular domain of the
receptor, inhibiting its function by blocking ligand binding
and receptor internalisation. Possibly, they can also trigger
an immune reaction against the EGFR expressing cell.
TKIs target the intracellular domain of the receptor,
inhibiting its tyrosine kinase activity and rendering the
receptor impotent (Harari 2004). Corkery et al. (2009)
evaluated the effect of the TKI geﬁtinib in combination
with docetaxel on TNBC cell lines and found higher
effectiveness of the combined therapy scheme. However,
as a monotherapy giﬁtinib seems to be ineffective, since
phase II studies showed very little beneﬁt from giﬁtinib
monotherapy in hormone resistant breast tumours (Green
et al. 2009; von Minckwitz et al. 2005). Unfortunately,
results for another TKI, lapatinib, were as disappointing by
showing very little clinical beneﬁt, except for HER2-
positive tumours (Burris et al. 2009). Other phase II studies
addressing the effectiveness of the monoclonal EGFR
antibody cetuximab are currently being performed. It
seems that inhibition of EGFR as a monotherapy is inef-
fective, but it can increase the effectiveness of adjuvant
chemotherapy (Oliveras-Ferraros et al. 2008). Cetuximab
has already been approved for use in metastatic colon
cancer. However, results in breast cancer are not yet con-
vincing for either TKIs or mAbs (Burness et al. 2010);
thus, more research is needed to study their potential
beneﬁts and improve their effectiveness.
Conclusions
Triple-negative breast tumours show high recurrence and
poor survival rates. Often, TNBC and BBC are assumed to
represent similar entities. In fact, TNBC and BBC share
certain similarities but are clearly not identical entities of
breast cancer. There is increasing evidence that points
towards a BRCA1-related pathway leading to the devel-
opment of a TNBBC subtype. Possibly, TNBBC develops
due to aberrations in this BRCA1-related pathway, whereas
mutations that are not related to this pathway may occur
randomly because of the genomic instability of the tumour
and may lead to NTN-BBC and NB-TNBC subtypes.
TNBBC shows a good initial response to chemotherapeutic
agents, especially to anthracyclines and taxanes. However,
in the neo-adjuvant setting, recurrence rates after patho-
logic complete response are high. Targeted therapies, like
PARP inhibitors and EGFR targeting agents, might repre-
sent further promising therapeutic options, but still need to
be evaluated in appropriate phase III clinical trials.
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